EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer
Authors:
- Michael HöpfnerMHMichael Höpfner
- Viola BaradariVBViola Baradari
- Detlef SchuppanDSDetlef Schuppan
- Hans ScherüblHSHans Scherübl
- 1 November 2005
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 70 (11) , 1568-1578
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Hepatocellular carcinomaThe Lancet, 2003
- The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An UpdateAnnals of Internal Medicine, 2003
- Hepatocyte growth factor, transforming growth factor α, and their receptors as combined markers of prognosis in hepatocellular carcinomaMolecular Carcinogenesis, 2003
- Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?The Oncologist, 2002
- Why the Epidermal Growth Factor Receptor? The Rationale for Cancer TherapyThe Oncologist, 2002
- International trends and patterns of primary liver cancerInternational Journal of Cancer, 2001
- Expression and clinical significance of erb-B receptor family in hepatocellular carcinomaBritish Journal of Cancer, 2001
- Trends in Survival of Patients With Hepatocellular Carcinoma Between 1977 and 1996 in the United StatesHepatology, 2001
- Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinomaLiver International, 1997
- Carcinogen-induced alteration in liver epidermal growth factor receptor distribution during the promotion stage of hepatocarcinogenesis in ratCancer Letters, 1997